// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Identification of a Novel Molecular Variant in the PTGS1 Gene that Causes a Loss of a Glycan in the Catalytic Domain, Defects in Platelet Thromboxane A2 Synthesis, and Bleeding

V. Palma-Barqueros - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Identifying and Reducing the Cause of Haemolysis in Coagulation Blood Samples due to Sample Transport in a Pneumatic Tube System

J. Cooper - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Immune Thrombocytopenia Treatment with Fostamatinib, a Spleen Tyrosine Kinase Inhibitor: Reducing the Risk of Thrombosis

N. Cooper - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Immune thrombocytopenia

Fostamatinib

Immune Tolerance Induction with Simoctocog Alfa in Patients with Haemophilia A: An Ongoing Multicentre Case Series from the UK

G.W. Hall - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

simoctocog alfa

Immunization with Recombinant Atherogenic Antigen (AHC) Does Not Enhance Susceptibility to Sepsis

M. Xia - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Sepsis

N/A

Immunization with Recombinant Atherogenic Antigen (AHC) Does Not Increase Susceptibility to Venous Thrombosis

M. Xia - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

PC-515

Impact of Ultralarge von Willebrand Factor (VWF) Multimers and Platelets in Cultured Endothelial Cells in Acute Immune-mediated Thrombotic Thrombocytopenic Purpura

C. Vendramin - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Thrombotic thrombocytopenic purpura

histamine

Important Role for SHARPIN in Supporting Platelet Linear Ubiquitination and Thrombus Formation

S.F. Moore - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Influence of Body Mass Index on Outcomes in Patients with Venous Thromboembolism: Insights from GARFIELD-VTE

J.I. Weitz - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Influence of Personality and Life Conditions on Depression, Anxiety and Cognitive Performance in 104 Patients Having Survived Acute Autoimmune Thrombotic Thrombocytopenic Purpura (iTTP)

T. Falter - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Thrombotic thrombocytopenic purpura

N/A

Inhibitory Effect of Heparin and Modified Heparin on Neutrophil Migration

J. Hogwood - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Heparin

Inter-Centre and Inter-Observer Agreement of Determination of DOACs in Urine Samples of Patients by Means of DOAC Dipstick Test

J. Harenberg - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

rivaroxaban

Interplay between the Tyrosine Kinases Chk, Csk and Phosphatase CD148 Is Critical for Regulating Platelets in Mice

Z. Nagy - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

L-Tyrosine

ISTH SSC Plasma Standard Lot #5 – Results in a UK National External Quality Assessment Scheme for Blood Coagulation (NEQAS BC) Exercise

I. Jennings - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fibrinogen (IV)

Joint Health Outcomes in Patients with Hemophilia A Receiving Antihemophilic Factor (Recombinant) in a Real-World Setting: Results of a 6-Year Interim Analysis of the AHEAD International Study

M.C. Ozelo - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

Antihemophilic factor

Laboratory Accuracy Assessment of a Novel INR Point-of-Care Test Compared with Laboratory Reference Methods Used Across Four Independent Clinical Sites

K. Taggart - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Long-Term Immunogenicity, Efficacy and Safety of Simoctocog Alfa in Patients with Severe Haemophilia A who Had Completed the NuProtect PUP Study

R.J. Liesner - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

simoctocog alfa

Longitudinal Analysis of rFVIIIFc Use and Efficacy in the UK: A Report from the National Haemophilia Database

C. Wall - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

FVIIIFc

Loss of the Exocyst Complex Component, EXOC3, Accelerates Arterial Thrombosis

T. Walsh - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Low 1-Year Venous Thromboembolic Recurrence Rates in Patients with and without Thrombotic Risk Factors in Routine Clinical Practice Treated with Edoxaban: The Global ETNA-VTE Study

A. Cohen - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Edoxaban

Copyright © 2026. QuantiNova All rights reserved